Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma

British Journal of Cancer volume 84, pages 465–469 (2001)Cite this article

This article has been updated

Abstract

Bryostatin 1 is a naturally occurring macrocyclic lactone with promising antitumour and immunomodulatory function in preclinical and phase I clinical investigations. In this phase II study, 17 patients with progressive non-Hodgkin’s lymphoma of indolent type (NHL), previously treated with chemotherapy, received a median of 6 (range 1–9) intravenous infusions of 25 μg/m2 bryostatin 1 given once weekly over 24 hours. In 14 evaluable patients no responses were seen. Stable disease was attained in one patient for 9 months. The principal toxicities were myalgia and phlebitis. Treatment was discontinued early because of toxicity alone (phlebitis) in 2 patients, toxicity in addition to progressive disease in 3 patients (myalgia and phlebitis n = 2; thrombocytopenia n = 1) and progressive disease in 5 patients. The results fail to demonstrate efficacy of this regimen of bryostatin 1 in the treatment of NHL. In light of preclinical data that demonstrate synergy between bryostatin 1 and several cytotoxic agents and cytokines, clinical studies to investigate bryostatin 1 in combination are warranted. We also present data to demonstrate that central venous lines may be used in future studies to avoid phlebitis. © 2001 Cancer Research Campaign

Download PDF

Change history

  • 16 November 2011

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

References

  • Al-Katib AM, Smith MR, Kamanda WS, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B and Mohammed RM (1998) Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 4: 1305–1314

    CAS  PubMed  Google Scholar 

  • Basu A and Lazo JS (1992) Sensitisation of human cervical carcinoma cells to cis-diamminediachloroplatinum(II) by bryostatin 1. Cancer Res 52(11): 3119–3124

    Google Scholar 

  • Berkow RL, Schlabach L, Dodson R, Benjamin WJ, Pettit GR, Rustagi P and Kraft AS (1993) In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res 53: 2810–2815

    CAS  PubMed  Google Scholar 

  • Buchner K (2000) The role of protein kinase C in the regulation of cell growth and in signalling to the cell nucleus. J Cancer Res Clin Oncol 126(1): 1–11

    Article  Google Scholar 

  • Cheung AP, Hallock YF, Vishnuvajjala BR, Nguyenle T and Wang E (1998). Invest New Drugs 16: 227–236

  • Elgie AW, Sargent JM, Alton P, Peters GJ, Noordhuis P, Williamson CJ and Taylor CG (1998) Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML. Leuk Res 22(4): 373–378

    Article  Google Scholar 

  • Gehan A (1961) The determination of the number of patients required in a preliminary and a follow up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346–353

    CAS  Article  Google Scholar 

  • Gonzalez R, Ebbinghaus S, Henthorn TK, Miller D and Kraft AS (1999) Treatment of patients with metastatic melanoma with bryostatin 1 – a phase II study. Melanoma Res 9(6): 599–606

    Article  Google Scholar 

  • Hickman PF, Kemp GJ, Thompson CH, Salisbury AJ, Wade K, Harris AL and Radda GK (1995) Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study. Br J Cancer 72(4): 998–1003

    Article  Google Scholar 

  • Hornung RL, Pearson JW, Beckwith M and Longo DL (1992) Preclinical evaluation of bryostatin as an anticancer agent against several murine tumour cell lines: in vitro versus in vivo activity. Cancer Res 52: 101–107

    CAS  PubMed  Google Scholar 

  • Jayson GC, Crowther D, Prendiville J, McGown A, Scheid C, Stern P, Young R, Brenchley P, Chang J and Owens S and Pettit GR (1995) A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. B J Cancer 72: 461–468

    CAS  Article  Google Scholar 

  • Kaubisch A, Kelsen DP, Saltz L, Kemeny N, O’Reilly E, Ilson D, Endres S, Barazzuol J and Schwartz GK (1999). A phase I trial of weekly sequential bryostatin-1 and paclitaxel in patients with advanced solid tumours,

  • Khan P, McGown AT, Dawson MJ, Jayson G, Prendiville JA, Pettit GR and Crowther D (1998) High Performance liquid chromatographic assay for the novel antitumour drug, bryostatin-1, incorporating a serum extraction technique. J Chromatogr B Biomed Sci Appl 709(1): 113–117

    Article  Google Scholar 

  • Koutcher JA, Motwani M, Zakian KL, Li XK, Matei C, Dyke JP, Ballon D, Yoo HH and Schwartz GK (2000) The in vivo effect of bryostatin 1 on paclitaxel-induced tumour growth mitotic entry, and blood flow. Clin Cancer Res 6(4): 1498–1507

    Google Scholar 

  • Maki A, Diwakaran H, Redman B, Al-Asfar S, Pettit GR, Mohammed RM and Al-Katib A (1995) The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anticancer Drugs 6: 392–397

    CAS  Article  Google Scholar 

  • May WS, Sharkis SJ, Esa AH, Gebbia U, Kraft AS, Pettit GR and Sensenbrenner L (1987) Antineoplastic bryostatins are multipotential stimulators of human haematopoietic progenitor cells. Proc Natl Acad Sci 84: 8483–8487

    CAS  Article  Google Scholar 

  • McGown AT, Jayson G, Pettit GR, Haran MS, Ward TH and Crowther D (1998) Bryostatin 1 – tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro. Br J Cancer 77(2): 216–220

    Article  Google Scholar 

  • Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1): 207–214

    Article  Google Scholar 

  • Mohammed RM, Al-Katib A, Pettit RG and Sensenbrenner LL (1993) Differential effects of bryostatin 1 on human non-Hodgkin’s lymphoma cell lines. Leukaemia Research 17: 1–8

    Article  Google Scholar 

  • Mohammed RM, Al-Katib Pettit GR and Sensenbrenner LL (1994) Successful treatment of human Waldenstrom’s macroglobulinaemia with combination biological and chemotherapy agents. Cancer Res 54: 165

    Google Scholar 

  • Mohammed RM, Diwakaran H, Maki A, Emara MA, Pettit GR, Redman B and Al-katib A (1995) Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk Res 19: 667–673

    Article  Google Scholar 

  • Mohammed RM, Beck FW, Katato K, Hardy N, Wall N and Al-Katib A (1998) Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukaemia cell line (WSU-CLL): association with increased ratios of dCK/5-NT and Bax/Bcl-2. Biol Chem 379(10): 1253–1261

    Google Scholar 

  • Nishizuka Y (1986) Studies and perspectives of protein kinase C. Science 233: 305–312

    CAS  Article  Google Scholar 

  • Pettit GR, Herald CL and Doubek DL (1982) Isolation and structure of bryostatin 1. J Am Chem soc 104: 6846–6848

    CAS  Article  Google Scholar 

  • Philip AP, Rea D, Thavasu P, Carmichael J, Stuart NSA, Rockett H, Talbot DC, Ganeson T, Pettit GR, Balkwill F and Harris AL (1993) Phase I study of bryostatin 1: Assessment of interleukin 6 and tumor necrosis factor α induction in vivo. J Natl Cancer Institute 85(22): 1812–1818

    Article  Google Scholar 

  • Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M and Pettit GR (1993) A Phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 68: 418–424

    CAS  Article  Google Scholar 

  • Propper DJ, Macaulay V, O’Byrne KJ, Braybrooke JP, Wilner SM, Ganesean TS, Talbot DC and Harris AL (1998) A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 78(10): 1337–1341

    Article  Google Scholar 

  • Rosenthal MA, Oratz R, Liebes L, Cahr MH and Muggia FM (1999). Phase I study of bryostatin-1 (NSC 339555) and Cisplatin in Advanced Malignancies,

  • Scheid C, Prendiville J, Jayson G, Crowther D, Fox B, Pettit GR and Stern PL (1994) Immunomodulation in patients receiving intravenous bryostatin 1 in a phase 1 clinical study: comparison with effects of bryostatin 1 on lymphocyte function in vitro. Cancer Immunol Immunother 39: 223–230

    CAS  Article  Google Scholar 

  • Sharkis SJ, Jones RJ, Bellis ML, Demitri GD, Griffin JD, Civin C and May WS (1990) The action of bryostatin on normal human haematopoietic progenitors is mediated by accessory cell release of growth factors. Blood 76: 716–720

    CAS  PubMed  Google Scholar 

  • Stansfeld AG, Diebold G, Noel H, Kapanci Y, Rilke F, Kelenyi G, Sundstrom C, Lennert K, van-Unnik JA and Mioduszewska O (1988) Updated Kiel Classification for lymphomas (letter). Lancet 1: 292–293

    CAS  Article  Google Scholar 

  • Thompson CH, Macaulay VM, O’Byrne KJ, Kemp GJ, Wilner SM, Talbot DC, Harris AL and Radda GK (1996) Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply. Br J Cancer 73(10): 1161–1165

    Article  Google Scholar 

  • Varterasian ML, Mohammed RM, Eilender DS, Hulbard K, Rodriguez DH, Pemberton PA, Pluda JM, Dan MD, Pettit GR, Chen BDM and Al-Katib AM (1998) Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. J Clin Oncol 16(1): 56–62

    Article  Google Scholar 

  • Varterasian ML, Mohammed RM, Shurafa MS, Hulbard K, Pemberton PA, Rodriguez DH, Spadoni V, Eilender DS, Murgo A, Wall N, Dan M and Al-Katib AM (2000) Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Clin Cancer Res 6: 825–828

    CAS  PubMed  Google Scholar 

  • Weitman S, Langevin AM, Berkow RL, Thomas PJ, Hurwitz CA, Kraft AS, Dubowy RL, Smith DL and Bernstein M (1999) A Phase I trial of bryostatin 1 in children with refractory solid tumours: a Pediatric Oncology Group study. Clin Cancer Res 5(9): 2344–2348

    Google Scholar 

  • Wojtowicz-Praga SM, Dickson RB and Hawkins MJ (1997) Matrix metalloproteinase inhibitors. Investigational New Drugs 15: 61–75

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

  1. CRC Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester

    F H Blackhall, M Ranson, J A Radford & G C Jayson

  2. YCRC Department of Clinical Oncology, Weston Park Hospital NHS Trust, Whitham Road, Sheffield

    B W Hancock

  3. Department of Medical Oncology, Royal Infirmary, 84 Castle Street, Glasgow

    M Soukop

  4. CRC Drug Development Group, Paterson Institute for Cancer Research, Wilmslow Road, Withington, Manchester

    A T McGown

  5. Drug Development Office, Cancer Research Campaign, 10 Cambridge Terrace, London

    A Robbins

  6. Department of Pharmaceutical Sciences, CRC Formulation Unit, University of Strathclyde, Royal College Building, 204 George Street, Glasgow, UK

    G Halbert

Authors
  1. F H Blackhall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Ranson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J A Radford
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B W Hancock
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Soukop
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A T McGown
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Robbins
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Halbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G C Jayson
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the Cancer Research Campaign Phase I/II Committee

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and Permissions

About this article

Cite this article

Blackhall, F., Ranson, M., Radford, J. et al. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Br J Cancer 84, 465–469 (2001). https://doi.org/10.1054/bjoc.2000.1624

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1054/bjoc.2000.1624

Keywords

  • bryostatin 1
  • non-Hodgkin’s lymphoma
  • protein kinase C inhibitors

Further reading

Search

Advanced search

Quick links